CD274 and hepatocellular carcinoma: IMbrave150 is the first global phase III randomized trial to determine the efficacy of atezolizumab (anti-PD-L1) in combination with bevacizumab (anti-VEGF) as the first line treatment for patients with unresectable HCC [119].